Dose to heart substructures is associated with non-cancer death after SBRT in stage I–II NSCLC patients

Publication date: Available online 2 May 2017
Source:Radiotherapy and Oncology
Author(s): Barbara Stam, Heike Peulen, Matthias Guckenberger, Frederick Mantel, Andrew Hope, Maria Werner-Wasik, Jose Belderbos, Inga Grills, Nicolette O'Connell, Jan-Jakob Sonke
Background and purposeTo investigate potential associations between dose to heart (sub)structures and non-cancer death, in early stage non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT).Methods803 patients with early stage NSCLC received SBRT with predominant schedules of 3×18Gy (59%) or 4×12Gy (19%). All patients were registered to an average anatomy, their planned dose deformed accordingly, and dosimetric parameters for heart substructures were obtained. Multivariate Cox regression and a sensitivity analysis were used to identify doses to heart substructures or heart region with a significant association with non-cancer death respectively.ResultsMedian follow-up was 34.8months. Two year Kaplan–Meier overall survival rate was 67%. Of the deceased patients, 26.8% died of cancer. Multivariate analysis showed that the maximum dose on the left atrium (median 6.5Gy EQD2, range=0.009–197, HR=1.005, p-value=0.035), and the dose to 90% of the superior vena cava (median 0.59Gy EQD2, range=0.003–70, HR=1.025, p-value=0.008) were significantly associated with non-cancer death. Sensitivity analysis identified the upper region of the heart (atria+vessels) to be significantly associated with non-cancer death.ConclusionsDoses to mainly the upper region of the heart were significantly associated with non-cancer death. Consequently, dose sparing in particular of the upper region of the heart could potentially improve outcome, and should be further studied.



http://ift.tt/2pEicBH